The beauty industry is making increasing reference to biotechnology in its marketing. In an intensely competitive market with countless products vying for attention, brands are looking for ways to differentiate and legitimise their claims. One of the most visible results of this shift has been the rise of peptide ingredients, with a broad range of associated claims for skincare, haircare, and beyond.
New advances in technology are set to expand this field even further, creating both opportunity and risk for beauty brands. Ignoring peptides — or relying solely on widely used, established ingredients — is becoming a high-risk strategy.
The coming market disruption
As biotechnology’s role in beauty deepens, its influence on consumer choice will grow. If consumers are presented with clear, credible evidence of which ingredients and products deliver the best results, this will inevitably guide their purchasing decisions.
This trend puts a premium on sourcing and developing the best peptide ingredients. It also raises critical challenges:
- How do you identify the most effective peptides for delivering defined benefits?
- How do you verify their performance?
- How do you manufacture them affordably, at the right quality and scale?
- And how do you formulate them into a finished product without losing their efficacy?
The unrealised potential in plain sight
Scientific literature is providing ever-greater insight into the molecular biology of skin and hair. AI tools now make it faster and easier to find promising “needles in the haystack” using this breadth of information. Endogenous proteins (those naturally found in skin) offer significant opportunities to enhance beauty products. This could mean creating synthetic equivalents of these proteins, or designing peptides to replicate their effects in a regulatory-compliant way.
Furthermore, the combination of AI and in-vitro assays makes it possible to screen extensive peptide libraries for candidates that deliver specific consumer benefits.
Yet a key constraint remains: the ability to manufacture these peptides, particularly when they are large and/or complex.
Why the value remains untapped
Many beauty companies have already identified proteins or peptides with great potential. Some may even hold libraries of promising candidates ready for screening. And yet, the value remains unrealised. Why?
The main barriers include:
- No viable means of commercial-scale manufacture for some peptides.
- No reliable process for screening and validating peptide performance.
- No way to protect the competitive advantage once a winning peptide is identified.
Without manufacturing viability and IP protection, there is little incentive to invest in discovering breakthrough peptides, because competitors could use the same ingredient.
A better solution
In-vitro assays and AI-driven in-silico screening technologies already exist, but they must be carefully selected, expertly operated, and tailored to the specific project context.
The bigger breakthrough lies in removing the manufacturing and IP hurdles that have held the industry back.
Phenotypeca’s QTL technology uses vast natural genetic diversity and the power of evolution to optimise the entire genome of Saccharomyces cerevisiae. This has created a proprietary library of yeast strains capable of producing a wide range of peptides — including those that are large or complex — at scale, high quality, and low cost.
These strains are protected by patents and know-how, meaning brands can secure exclusive rights to use peptides made with them. This protection prevents competitors from manufacturing the same peptides or using equivalent strains.
Conclusion
Branding, marketing, packaging, design, and sensory experience have always been critical in beauty. These will remain important, but the entry of robust science is set to disrupt the industry.
Peptides are at the centre of this transformation. Their wide-ranging potential has remained largely untapped, but with the right science and technology, this opportunity can finally be realised. Brands that identify or develop the right peptides and, critically, secure the means to produce and protect them, will gain a significant competitive edge.
The rewards for success are substantial. The risks of inaction are real. Entering this race no longer requires a king’s ransom — just the right technology partner.
